At a glance

ClinicalIndex Comparison Record

Phase 1Completed· 40 enrolled

Drug / intervention

Dexanabinol Dose Level 1 +5 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02054754

NCT02054754Phase 1Completed

Compare CT.gov

Assessment of Safety, Tolerability and Pharmacokinetics of Single Doses of Oral Dexanabinol in Healthy Subjects

e-Therapeutics PLC·interventional·Posted Feb 4, 2014·Updated May 23, 2016

In Brief

A Phase 1 clinical trial evaluating Dexanabinol Dose Level 1, Dexanabinol Dose Level 2, and 4 other interventions for Safety and 3 related conditions. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to test the safety and observe the pharmacokinetics (distribution and elimination of the drug) of the compound dexanabinol (ETS2101) in healthy male subjects following a single oral dose.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsSafety, Tolerability, Pharmacokinetics, Cancer

CountriesUnited Kingdom

Collaborators--

Timeline

Phase 1CompletedFinished

2014201520162017201820192020202120222023202420252026

Enrollment StartJan 2014

First PostedFeb 2014

Primary CompletionSep 2014

TodayJul 2026

First PostedFeb 4, 2014

Enrollment StartJan 1, 2014

Primary CompletionSep 1, 2014

TodayJul 2, 2026

Enrollment to primary: 8 monthsPosted 12.4 years ago